Shares of Johnson Matthey PLC (LON:JMAT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is GBX 2,283.33.
JMAT has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 2,400 price objective on shares of Johnson Matthey in a research report on Monday, July 6th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,330 price target on shares of Johnson Matthey in a research note on Tuesday, August 4th. Berenberg Bank upped their price objective on shares of Johnson Matthey from GBX 2,100 to GBX 2,300 and gave the stock a “buy” rating in a report on Monday, June 1st. Finally, UBS Group reissued a “neutral” rating and issued a GBX 2,200 price objective on shares of Johnson Matthey in a research note on Friday, May 22nd.
View Our Latest Analysis on Johnson Matthey
Johnson Matthey Trading Up 0.1%
Insiders Place Their Bets
In related news, insider Richard Pike bought 14 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was purchased at an average cost of GBX 1,990 per share, for a total transaction of £278.60. Also, insider Alastair Judge bought 14 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of GBX 1,990 per share, for a total transaction of £278.60. Insiders acquired a total of 90 shares of company stock worth $178,458 over the last 90 days. Corporate insiders own 0.58% of the company’s stock.
About Johnson Matthey
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources. Today more than 13,000 Johnson Matthey professionals collaborate with their network of customers and partners to make a real difference to the world around us.
See Also
- Five stocks we like better than Johnson Matthey
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.
